Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pasithea Therapeutics Corp. Warrant (KTTAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: KTTAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.24% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6931236 |
Shares Outstanding - | Shares Floating 6931236 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pasithea Therapeutics Corp. Warrant
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. The warrant is tied to their stock.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutics for neurological and psychiatric disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
Leadership and Structure
Details on the leadership team and organizational structure were unavailable without live data access.
Top Products and Market Share
Key Offerings
- PAS-004: PAS-004 is a preclinical asset that is under development. The company is looking for a strategic partner to further progress PAS-004.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with a focus on developing innovative treatments for unmet medical needs.
Positioning
Pasithea is an early stage company in the CNS disorder space, seeking to establish a presence through innovative therapies. Their market positioning is based on novel therapeutic approaches.
Total Addressable Market (TAM)
TAM depends on the specific CNS disorders targeted. The overall CNS therapeutic market is substantial. Pasithea's positioning relative to TAM depends on successfully developing and commercializing their pipeline.
Upturn SWOT Analysis
Strengths
- Innovative therapeutic approaches
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Early stage development
- Limited financial resources
- High regulatory risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
Competitors and Market Share
Key Competitors
Competitive Landscape
Pasithea faces competition from established pharmaceutical companies and other biotechnology firms in the CNS therapeutic area.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the underlying company's performance.
Future Projections: Future projections depend on analyst estimates for Pasithea Therapeutics Corp. and warrant market dynamics.
Recent Initiatives: Recent initiatives include clinical trial progress and strategic partnerships.
Summary
Pasithea Therapeutics Corp. is an early-stage biotechnology company focused on developing novel therapeutics for CNS disorders. It faces typical challenges for biotech companies including regulatory risks and the need for substantial capital. The company's success hinges on successful clinical trials and commercialization of its pipeline. The warrant's value is derived from the underlying stock performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The value of warrants is highly volatile and speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.